Clinical trial
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With…
NCT00493116 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00493116 |
|---|---|
| Title | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta |
| Official title | A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability |
| Acronym | RENeu |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon-beta-1a, methylprednisolone |
| Enrollment | 20 |
| Start date | Oct 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 27, 2007 |
| Last update posted | Sep 16, 2013 |
| Countries | Australia, New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: